Optimising HIV drug resistance testing laboratory networks in Kenya: insights from systems engineering modelling

被引:0
|
作者
Wang, Yinsheng [1 ]
Kingwara, Leonard [2 ]
Wagner, Anjuli Dawn [3 ]
Yongo, Nashon [4 ]
Hassan, Shukri A. [5 ]
Liu, Shan [6 ]
Oyaro, Patrick [7 ]
Patel, Rena C. [8 ,9 ]
机构
[1] Univ Washington, Dept Ind & Syst Engn, Seattle, WA 98195 USA
[2] Kenya Minist Hlth, Natl HIV Reference Lab, Nairobi, Kenya
[3] Univ Washington, Dept Global Hlth, Seattle, WA USA
[4] Univ Washington, Kenya Res & Training Ctr, Seattle, WA USA
[5] Univ Washington, Seattle, WA USA
[6] Univ Washington, Dept Ind & Syst Engn, Seattle, WA USA
[7] Hlth Innovat Kenya HIK, Kisumu, Kenya
[8] Univ Washington, Dept Med, Seattle, WA USA
[9] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA
来源
BMJ OPEN | 2024年 / 14卷 / 04期
关键词
HIV & AIDS; Decision Making; Health policy; POINT-OF-CARE; MIDDLE-INCOME COUNTRIES; SUB-SAHARAN AFRICA; ANTIRETROVIRAL THERAPY; 2ND-LINE TREATMENT; NON-INFERIORITY; OPEN-LABEL; DOLUTEGRAVIR; INFECTION; HEALTH;
D O I
10.1136/bmjopen-2023-079988
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background HIV drug resistance (DR) is a growing threat to the durability of current and future HIV treatment success. DR testing (DRT) technologies are very expensive and specialised, relying on centralised laboratories in most low and middle-income countries. Modelling for laboratory network with point-of-care (POC) DRT assays to minimise turnaround time (TAT), is urgently needed to meet the growing demand. Methods We developed a model with user-friendly interface using integer programming and queueing theory to improve the DRT system in Kisumu County, Kenya. We estimated DRT demand based on both current and idealised scenarios and evaluated a centralised laboratory-only network and an optimised POC DRT network. A one-way sensitivity analysis of key user inputs was conducted. Results In a centralised laboratory-only network, the mean TAT ranged from 8.52 to 8.55 working days, and the system could not handle a demand proportion exceeding 1.6%. In contrast, the mean TAT for POC DRT network ranged from 1.13 to 2.11 working days, with demand proportion up to 4.8%. Sensitivity analyses showed that expanding DRT hubs reduces mean TAT substantially while increasing the processing rate at national labs had minimal effect. For instance, doubling the current service rate at national labs reduced the mean TAT by only 0.0%-1.9% in various tested scenarios, whereas doubling the current service rate at DRT hubs reduced the mean TAT by 37.5%-49.8%. In addition, faster batching modes and transportation were important factors influencing the mean TAT. Conclusions Our model offers decision-makers an informed framework for improving the DRT system using POC in Kenya. POC DRT networks substantially reduce mean TAT and can handle a higher demand proportion than a centralised laboratory-only network, especially for children and pregnant women living with HIV, where there is an immediate push to use DRT results for patient case management.
引用
收藏
页数:11
相关论文
共 46 条
  • [41] Surveillance of Transmitted HIV Drug Resistance Using Matched Plasma and Dried Blood Spot Specimens From Voluntary Counseling and Testing Sites in Ho Chi Minh City, Vietnam, 2007-2008
    Duc, Nguyen Bui
    Hien, Bui Thu
    Wagar, Nick
    Tran Hong Tram
    Le Truong Giang
    Yang, Chunfu
    Wolfe, Mitchell I.
    Nguyen Tran Hien
    Nguyen Anh Tuan
    [J]. CLINICAL INFECTIOUS DISEASES, 2012, 54 : S343 - S347
  • [42] HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon
    Takou, Desire
    Fokam, Joseph
    Teto, Georges
    Santoro, Maria-Mercedes
    Ceccherini-Silberstein, Francesca
    Nanfack, Aubin Joseph
    Sosso, Samuel Martin
    Dambaya, Beatrice
    Salpini, Romina
    Billong, Serge Clotaire
    Gori, Caterina
    Fokunang, Charles Ntungwen
    Cappelli, Giulia
    Colizzi, Vittorio
    Perno, Carlo-Federico
    Ndjolo, Alexis
    [J]. BMC INFECTIOUS DISEASES, 2019, 19 (1)
  • [43] Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting
    Zazzi, Maurizio
    Prosperi, Mattia
    Vicenti, Ilaria
    Di Giambenedetto, Simona
    Callegaro, Annapaola
    Bruzzone, Bianca
    Baldanti, Fausto
    Gonnelli, Angela
    Boeri, Enzo
    Paolini, Elisabetta
    Rusconi, Stefano
    Giacometti, Andrea
    Maggiolo, Franco
    Menzo, Stefano
    De Luca, Andrea
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (03) : 616 - 624
  • [44] HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon
    Desire Takou
    Joseph Fokam
    Georges Teto
    Maria-Mercedes Santoro
    Francesca Ceccherini-Silberstein
    Aubin Joseph Nanfack
    Samuel Martin Sosso
    Béatrice Dambaya
    Romina Salpini
    Serge Clotaire Billong
    Caterina Gori
    Charles Ntungwen Fokunang
    Giulia Cappelli
    Vittorio Colizzi
    Carlo-Federico Perno
    Alexis Ndjolo
    [J]. BMC Infectious Diseases, 19
  • [45] Impact of point-of-care HIV viral load and targeted drug resistance mutation testing on viral suppression among Kenyan pregnant and postpartum women: results from a prospective cohort study (Opt4Mamas)
    Patel, Rena C.
    Oyaro, Patrick
    Thomas, Katherine K.
    Basha, Garoma Wakjira
    Wagude, James
    Mukui, Irene
    Brown, Evelyn
    Hassan, Shukri A.
    Kinywa, Eunice
    Oluoch, Fredrick
    Odhiambo, Francesca
    Oyaro, Boaz
    Kingwara, Leonard
    Karauki, Enericah
    Yongo, Nashon
    Otieno, Lindah
    John-Stewart, Grace C.
    Abuogi, Lisa L.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26 (11)
  • [46] Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations
    Hu, Guo-Dong
    Zhu, Tong
    Zhang, Shao-Long
    Wang, Dunyou
    Zhang, Qing-Gang
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (01) : 227 - 235